Refine by
Patient Access Articles & Analysis
233 news found
Guardant Health announces that a blood-based colorectal cancer screening option has been added by a cancer group, expanding noninvasive screening pathways for eligible individuals.The cancer group now lists a blood test as an additional colorectal cancer screening option, reflecting a shift toward noninvasive screening modalities.Clinicians and healthcare systems may experience implications for ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced it has successfully achieved ISO/IEC 27017:2015 and ISO/IEC 27018:2019 certifications for information security and privacy protection in its cloud services from BSI, the business improvement and standards company. It has also achieved recertification to ISO/IEC ...
Protheragen-ING has recently announced its ability to provide freeze-drying flash-release formulation development services to clients involved in drug discovery and development worldwide. Lyophilized flash-release formulations are advanced drug delivery systems that incorporate the benefits of both lyophilization and flash-release technologies. “Whether customers are trying to develop a ...
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to oncology guidelines each year make it ...
ByTempus
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that ...
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ ...
Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen ...
JUNE Medical is delighted to announce a new agreement with a major US hospital group to supply the award-winning Galaxy II® self-retaining surgical retractors to over 1,600 hospitals in the US, commencing April 15, 2023. This game-changing device radically improves the safety and ease of surgical retraction for both patients and medical staff; its ergonomic design transforms the way in which ...
On July 15, 2021, The openning ceremony of a new state of the art peptide manufacture facility was held in Jintang, Chengdu. The successful completion of the facility marks the successful industrialization of Aikening® in Jintang. Aiming at intelligent manufacturing, high efficiency and eco system, and a quality system to be certified by the US FDA, EU EMA and China NMPA, the peptide ...
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need. The Menarini Group (“Menarini”), a ...
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel alone, with similar overall rates of adverse events between study arms European Commission decision on granting a marketing authorization is anticipated within ...
ByBayer AG
Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI® will use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, ...
For over 40 years, LifeScan’s vision has been to create a world without limits for people with diabetes and related conditions, and this remains as strong today as ever, and perhaps when our support is needed most. Therefore, we are responding to the urgent humanitarian need for diabetes health medical supplies resulting from the invasion of Ukraine. As part of our longstanding commitment ...
ByLifeScan
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. ...
ByxCures
Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. This strategic partnership will lay the groundwork for future collaborations by using AIR to aid ...
Coralville, Iowa December 7, 2022 — Digital Diagnostics – a leading AI diagnostics company on a mission to transform global healthcare – is a recipient of CB Insights’ fourth-annual Digital Health 150. The list recognizes the 150 most promising private digital health companies of 2022. “From reimagining clinical care, to leveraging tech like AR/VR to improve ...
We are happy to announce that the #simeox device is now commercially available in Canada. Proud to partner with Novus Medical to help respiratory clinicians improve the life of their patients through access to Simeox. The Simeox device is an efficient and comfortable therapy for distal mucus clearance – for patients suffering from chronic lung conditions associated with chest congestion, ...
Last month, the 21st Century Cures Act forced healthcare organizations to provide patients quick and easy access to their health records in a digital format. In response to the news, xCures is happy to announce that patients using their platform, can now automatically retrieve their medical records from the institutions where they received care, and get instant access to a powerful care ...
ByxCures
Galapagos NV (Euronext & NASDAQ: GLPG) today held its R&D Day 2022, featuring presentations of key opinion leaders and company management on the strategic, scientific, and commercial progress at the company. The company also presented its financial results for the third quarter of 2022. Paul Stoffels3, CEO and Chairman of the Board of Directors of Galapagos, commented: “Today we ...
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within selected managed care health systems. ...